Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005594 · ClinicalTrials.gov registry record · Phase 2
ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00005594: Completed Phase 2 study, sponsored by University of Alabama at Birmingham.
NCT00005594 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005594, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ISIS 2503 in treating patients who have advanced cancer of the pancreas.
Interventions
- DRUG ISIS 2503
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2000-07 |
| Phase | Phase 2 |
What the finished NCT00005594 record still lists
NCT00005594 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which ISIS 2503 is the first listed.
NCT00005594 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005594 about?
NCT00005594 is a clinical study titled "ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ISIS 2503 in treating patients who have advanced cancer of the pancreas.
What is the current status of trial NCT00005594?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2000-07.
What interventions are being tested in trial NCT00005594?
The interventions under investigation include: ISIS 2503 (DRUG).
Who is sponsoring clinical trial NCT00005594?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00005594's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia